UNASSIGNED: Haploidentical hematopoietic stem cell transplantation (HSCT) performed using bone marrow (BM) grafts and post-transplantation cyclophosphamide (PTCy) has gained much interest for the excellent @entity137 profile after both reduced-intensity and myeloablative conditioning. We investigated, in a cohort of 40 high-risk hematological @entity1 , the feasibility of peripheral blood stem cells grafts after a @entity21193 -melphalan myeloablative conditioning, followed by a PTCy and @entity3446 -based @entity2132 ( @entity2132 ) prophylaxis (Sir-PTCy). Donor engraftment occurred in all @entity1 , with full donor chimerism achieved by day 30. Post-HSCT recovery of lymphocyte subsets was broad and fast, with a median time to @entity404 > 200/ L of 41 days. Cumulative incidences of grade II to IV and III-IV acute @entity2132 were 15% and 7.5%, respectively, and were associated with a significant early increase in circulating regulatory T cells at day 15 after HSCT, with values < 5% being predictive of subsequent @entity2132 occurrence. The 1-year cumulative incidence of chronic @entity2132 was 20%. Nonrelapse mortality (NRM) at 100 days and 1 year were 12% and 17%, respectively. With a median follow-up for living @entity1 of 15 months, the estimated 1-year overall and disease-free survival (DFS) was 56% and 48%, respectively. Outcomes were more favorable in @entity1 who underwent transplantation in complete remission (1-year DFS 71%) versus @entity1 who underwent transplantation with active disease (DFS, 34%; P  = .01). Overall, myeloablative haploidentical HSCT with peripheral blood stem cells (PBSC) and Sir-PTCy is a feasible treatment option: the low rates of @entity2132 and NRM as well as the favorable immune reconstitution profile pave the way for a prospective comparative trial comparing BM and PBSC in this specific transplantation setting.

Post-transplantation Cyclophosphamide and @entity3446 after Haploidentical Hematopoietic Stem Cell Transplantation Using a XXXX -based Myeloablative Conditioning and Peripheral Blood Stem Cells.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-versus-host disease'] @entity21193 :: ('MESH:C018404', 'Chemical') :: ['treosulfan']
@entity21193 :: (MESH:C018404,Chemical) :: ['Treosulfan']
